Abstract: This invention relates, to a method for promoting CNS axon regeneration, comprising (1) inhibiting the expression or activity in a neuron of one or more of the members of the Krüppel-like transcription factor (KLF) family that suppress axon growth (e.g., KLF 1, 2, 3, 4, 5, 9,12, 13, 14, 15 and/or 16), and/or (2) stimulating the expression or activity in a neuron of one or more of the members of the KLF family that promote axon growth (e.g., KLF 6 and/or 7).

Abstract: A method of thermally inducing and monitoring changes to localized regions of tissue by illuminating a volume of tissue with a first beam of X-rays, detecting portions of the first beam that passed through the volume, generating a first image signal from the portions of the first beam detected, applying heat to at least a localized region of tissue within the volume after the illuminating and detecting, illuminating the volume with a second beam of X-rays, detecting portions of the second beam that passed through the volume during the illuminating with the second beam, generating a second image signal from the portions of the second beam detected, and generating a difference image signal based upon a comparison of the first and second image signals. The difference image signal provides information of changes in X-ray attenuation by localized regions of tissue within the volume due to the application of heat.

Abstract: Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: Provided is a cell culture apparatus for culturing cells, that provides enhanced oxygen delivery and supply to cells without the need for stirring or sparging. Oxygen diffusion occurs on both sides of the culture vessel, top and bottom. A gas-permeable membrane that includes perfluorocarbons in its composition allows for the rapid, enhanced and uniform transfer of oxygen between the environment of cells or tissues contained in the cell culture container apparatus and the atmosphere of the incubator in which the cell culture apparatus is incubated.

Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.

Abstract: Compositions and methods of activating dendritic cells with LMP1 and LMP1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. LMP1 or LMP1-CD40 chimeric protein may be used to activate and mature dendritic cells. LMP1 and LMP1-activated dendritic cells act as an adjuvant to enhance the cellular immune response. Also disclosed herein are kits for activating dendritic cells and for preparing a vaccine formulation. Administration of the dendritic cells transfected with LMP1 can induce an immune response against cancer or infection. The mature dendritic cells may comprise an antigen and at least one cytokine in addition to LMP1.

Abstract: Methods and compositions are provided for diagnosing an abnormal early pregnancy in a mammalian subject by contacting a biological sample of the subject with a reagent that enables measurement of certain biomarker targets, e.g., human placental lactogen (hPL) and/or human chorionic gonadotropin (hCG). In one embodiment, the mRNA of these biomarkers is measured in a biological sample, e.g., serum. The absolute levels of mRNA or protein levels, a ratio of mRNA to protein levels, or a pattern of multiple biomarker mRNA and/or protein levels or ratios are measured and a relation to the ratio or pattern of expression levels of the same biomarkers in the same biological fluid of a reference or control female mammalian subject having a normal intrauterine pregnancy (IUP) is determined. The presence of, absence of, or changes in expression levels, ratios or patterns of the biomarker(s) in relation to those of the reference or control correlates with a diagnosis of abnormal pregnancy, i.e.

Abstract: This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof.

Abstract: Compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the treatment of many diseases.

Abstract: A computer system having a processor, non-transitory memory and a communication system is described. The communication system is coupled to a network and communicates with one or more genetic databases using an internet protocol. The non-transitory memory stores processor executable code to cause the processor to (1) receive data indicative of genetic array data of a patient via the communication system, (2) conduct, via the communication system and the network, at least one query of one or more genetic databases of genotypic data and phenotypic data using the data indicative of patient genetic data and phenotypic data, and (3) provide results of the at least one query to provide a clinical synopsis of the patient.

Abstract: Whether the growth hormone (GH)/Insulin-like growth factor 1(IGF-I) axis exerts cardioprotective effects remains controversial; and the underlying mechanism(s) for such actions are unclear. Here we tested the hypothesis that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 ?g/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function.

Abstract: Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: Described herein are pharmaceutical compositions including a sugar or mannose analog (e.g., 2-DG) and an inhibitor of at least one of PERK and GCN2 (e.g., an inhibitor of PERK and an inhibitor of GCN2) for treating cancer, and methods of treating cancer in a subject involving administration of these pharmaceutical compositions. Pharmaceutical compositions [or inducing death of cancer cells include a therapeutically effective amount of a pharmaceutical composition including: a pharmaceutically acceptable carrier, a sugar analog in an amount effective for inhibiting the growth of cancer cells, and an inhibitor of at least one of: PERK and GCN2 in an amount effective for blocking phosphorylation of eif2-1?t in the cancer cells, wherein the combined amounts of the sugar analog and the inhibitor of at least one of: PERK and GCN2 are sufficient for inducing death of the cancer cells.

Abstract: The present invention provides an aircraft having one or more fixed wings in a flying wing configuration, where the aircraft further includes a high performance co-flow jet (CFJ) circulating about at least a portion of an aircraft surface to produce both lift and thrust.

Abstract: A method secures data in a network. The data includes a data message that has a first bit length. A random number is generated and transformed to create a first pseudo random number. The first pseudo random number is mixed with the data message to create an encrypted message. The encrypted message is transformed into a second pseudo random number. The second pseudo random number is mixed with the random number to produce a key. The encrypted message is placed side-by-side with the key to produce an output message. The output message is dispersed into a plurality of fragments. The plurality of fragments is stored in a plurality of data storage devices.

Abstract: Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g., gp96), depletion of B cells in the subject, or both. Antigen (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. For example, the epitope bound in an immunogenic complex with the secreted heat shock protein may be obtained from allogeneic cancer cells coexpressing both secreted gp96 and antigen, or from syngeneic cancer cells of the subject expressing only antigen.

Abstract: The present invention provides for a biocompatible drug delivery device for the targeted treatment of cancer that is implantable within the tumorous mass of a patient. In one embodiment, the device comprises two polarizable elements mechanically coupled by a connecting element. The device also comprises one or more cancer treatment agents. When the polarizable elements are depolarized, such as by the application of ionizing radiation, the two polarizable elements are repelled from each other and release the cancer treatment agent. In another embodiment, one or more treatment agents are expelled from a miniaturized syringe when internal pressure of the device is increased by the production of gas bubbles in response to the application of ionizing radiation.